Promising New Treatments for MS: VIDEO

MS is a chronic disease that affects the nervous system. Nerves are coated in a protective covering called myelin, which also speeds up the transmission of nerve signals. People with MS experience progressive deterioration of myelin.


Effect of Amprya (Fampridine-PR (prolonged released 4-aminopyridine)) on the manual functions of patients with MS: STUDY

Image Source: HEALTH

Effect of Ampyra (Fampridine-PR / prolonged released 4-aminopyridine) on the manual functions of patients with MS: STUDY

Image Source: DRUGS.COM

MS Patients Show Better Gait and Balance with Ampyra (Dalfampridine) Treatment

Withdrawal/reinitiation study expands on known walking speed benefits of approved MS therapy

In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the International Journal of MS Care.

Safety profile of Ampyra (dalfampridine) extended release in MSs: 5-year postmarketing experience in the United States: STUDY

Image Source: HEALTH

Effects of Ampyra (dalfampridine) Extended-Release Tablets on 6-Minute Walk Distance in Patients With MS: A Post Hoc Analysis of a Double-Blind, Placebo-Controlled Trial: STUDY

Image Source: ALEXXBACIU